Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Fluconazole × Gastrointestinal × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 5 Other hematologic neoplasm 4 Myeloid 3 Plasma cell 2 Other solid neoplasm 2 Head & Neck 2 Gynecologic 2 Genitourinary 2 CNS 2 Breast 2 Tumor-Agnostic 1 Thoracic 1 Sarcoma 1 Gastrointestinal 1 Dermatologic 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Fluorouracil 554 Oxaliplatin 515 Gemcitabine 442 Capecitabine 403 Leucovorin 386 Irinotecan 349 Bevacizumab 296 Cisplatin 292 Radiotherapy 224 Cetuximab 189 Sorafenib 149 Docetaxel 135 pembrolizumab 123 Paclitaxel 123 Nivolumab 112 Albumin-Bound Paclitaxel 94 Folfox protocol 92 130-nm albumin-bound paclitaxel 89 Erlotinib Hydrochloride 88 Panitumumab 84 S 1 (combination) 78 regorafenib 74 Surgical Procedures, Operative 74 Drug Therapy 74 Radiation 61 Neoadjuvant Therapy 58 Carboplatin 56 Radiosurgery 55 Colonoscopy 54 Surveys and Questionnaires 53

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01686607 2024-10-21

MYCOS

Astellas Pharma Inc

40,110 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡